| 000 | 01822 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518030831.0 | ||
| 264 | 0 | _c20200213 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1873-2968 | ||
| 024 | 7 |
_a10.1016/j.bcp.2019.03.025 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRajesh, Y | |
| 245 | 0 | 0 |
_aTargeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. _h[electronic resource] |
| 260 |
_bBiochemical pharmacology _c06 2019 |
||
| 300 |
_a1-16 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
| 650 | 0 | 4 | _aBase Sequence |
| 650 | 0 | 4 |
_aBrain Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Delivery Systems _xmethods |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 |
_aGlioblastoma _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 2 _xgenetics |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aNF-E2-Related Factor 2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aProtein Structure, Tertiary |
| 650 | 0 | 4 |
_aTemozolomide _xadministration & dosage |
| 650 | 0 | 4 |
_aTranscription Factors _xantagonists & inhibitors |
| 700 | 1 | _aBiswas, Angana | |
| 700 | 1 | _aKumar, Utkarsh | |
| 700 | 1 | _aDas, Subhayan | |
| 700 | 1 | _aBanerjee, Indranil | |
| 700 | 1 | _aBanik, Payel | |
| 700 | 1 | _aBharti, Rashmi | |
| 700 | 1 | _aNayak, Santoshi | |
| 700 | 1 | _aGhosh, Sudip K | |
| 700 | 1 | _aMandal, Mahitosh | |
| 773 | 0 |
_tBiochemical pharmacology _gvol. 164 _gp. 1-16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bcp.2019.03.025 _zAvailable from publisher's website |
| 999 |
_c29491514 _d29491514 |
||